Technology
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.
The agency acknowledges its staff can't keep up with the volume of cell and gene therapy products and is looking to PDUFA VII for additional funds.Â
Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.